Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04002362 · ClinicalTrials.gov registry record · Phase 2
Symptom Clusters in Children With Exacerbation-prone Asthma
A Phase 2 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT04002362 is a Phase 2 study that has completed, run by Emory University. The registered enrollment target is 68 participants.
The verdict
NCT04002362, a Phase 2 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
Pediatric participants with exacerbation-prone asthma will receive an intramuscular injection of triamcinolone acetonide and will be followed for 48 weeks. The study visit 2 weeks after the injection will assess the response to the study medication, while the remaining study visits will examine the temporal stability of the symptom clusters.
Interventions
- DRUG Triamcinolone Acetonide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2019-11-13 |
| Est. Completion | 2025-12-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04002362
The ClinicalTrials.gov registry entry for NCT04002362 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Triamcinolone Acetonide is the first listed.
NCT04002362 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04002362 about?
NCT04002362 is a clinical study titled "Symptom Clusters in Children With Exacerbation-prone Asthma". Pediatric participants with exacerbation-prone asthma will receive an intramuscular injection of triamcinolone acetonide and will be followed for 48 weeks. The study visit 2 weeks after the injection will assess the response to the study medication, while the remaining study visits will examine the ...
What is the current status of trial NCT04002362?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2019-11-13. Estimated completion is 2025-12-24.
What interventions are being tested in trial NCT04002362?
The interventions under investigation include: Triamcinolone Acetonide (DRUG).
Who is sponsoring clinical trial NCT04002362?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.